32 results about "Tlr4 signaling" patented technology

Treatment of autoimmune and / or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and / or TLR3 / TLR4 signaling in nonimmune cells, monocytes, macrophages, and / or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and / or TLR3 / TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and / or TLR3 / TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3 / Type 1 IFN / STAT / ISRE / IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

The invention discloses a traditional Chinese medicine preparation and its preparation and application. The preparation is made from the following raw materials by weight: 20-30 parts of Astragalus root, 20-30 parts of Nansha ginseng, 20-30 parts of Beisha ginseng, and 10-30 parts of Lily Radix. 20 servings, 5-15 servings of dendrobium, 10-20 servings of aster, 10-20 servings of loquat leaves, 10-20 servings of bitter almond, 10-20 servings of Bai Bu, and 10-20 servings of angelica. It has the functions of clearing the lungs, relieving cough and relieving asthma, nourishing qi, nourishing yin and promoting blood circulation. After taking, the drug can directly act on the lesions of radiation pneumonia, inhibit the exudation of inflammatory cells in the alveolar wall, pulmonary interstitial congestion, hemorrhage, edema and alveolar structure damage, reduce the TLR4 signaling pathway signaling molecule protein and local lung. The expression of cytokines in tissue-related cells can reduce the inflammatory response of the lungs and achieve the purpose of delaying or treating radiation pneumonitis.

The present invention relates to a peptide for inhibiting a TLR4 signal transmission pathway, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. In more detail, peptides that bind to TLR4 / MD2 complexes to inhibit the secretion of interleukin-6 (IL-6), NO and ROS, and the activation of NFκB and MAPKs, TLR4 antagonists containing the above peptides, autoimmune diseases And a composition for the prevention or treatment of inflammatory diseases. The peptide of the present invention has an excellent effect of inhibiting the secretion of interleukin-6 (IL-6), NO and ROS and the activation of NFκB and MAPKs by inhibiting the TLR4 signal transmission pathway induced by lipopolysaccharide (LPS). The composition for preventing or treating autoimmune diseases and inflammatory diseases in which the TLR4 signal transmission pathway occurs is effectively utilized.